ABSTRACT
Aspiration therapy with AspireAssist is a novel endoscopic obesity treatment. Patients aspirate approximately 30% of an ingested meal through a draining system connected to a percutanous endoscopic gastrostomy tube. AspireAssist was recently approved by the US Food and Drug Administration, and it induces weight loss comparable to the weight loss observed after bariatric surgery, but with a lower risk of complications. Few clinical studies about the efficacy and safety of AspireAssist have been carried out and published. Thus, further intervention studies evaluating acute as well as long-term effects are warranted.
Subject(s)
Endoscopy, Gastrointestinal/methods , Obesity/therapy , Suction/methods , Denmark , Device Approval , Diabetes Mellitus, Type 2/therapy , Endoscopy, Gastrointestinal/adverse effects , Feeding Behavior , Gastrostomy/adverse effects , Gastrostomy/methods , Humans , Quality of Life , Suction/adverse effects , Weight LossABSTRACT
Roux-en-Y gastric bypass (RYGBP) is an increasingly used procedure when treating morbid obesity. Due to the extensive gastrointestinal rearrangement, diagnostic evaluation of patients with gastric bypass and acute abdominal pain can be difficult. We present a case of a perforated duodenal ulcer in a RYGBP operated patient, where free abdominal fluid, but hardly any pneumoperitoneum was seen on a computed tomography. Free intraperitoneal fluid is an important finding and should give suspicion of the need for emergency surgery in RYGBP operated patients with abdominal pain.
